(P-741) Dalbavancin Rationale and Clinical Outcomes in Patients Hospitalized with Serious Bacterial Infections at an Urban Safety Net Hospital: an Observational Cohort

Thursday, October 17, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

AR

Amanda Roy, PharmD

Clinical Infectious Diseases Pharmacist
Zuckerberg San Francisco General Hospital & Trauma Center/UCSF
San Francisco, California, United States
Ayesha Ashley Appa, MD (she/her/hers)

Fellow
UCSF Infectious Diseases & Addiction Medicine
Mill Valley, California, United States
BB

Bruno Bellman, PharmD

Zuckerberg San Francisco General Hospital and Trauma Center
San Jose, California, United States
AB

Andrew Banh, PharmD

Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California, United States
NC

Nicholas Campalans, MD

UCSF
San Francisco, California, United States
BH

Beatrice Huang, BA

Clinical Research Manager/Project Coordinator
Zuckerberg San Francisco General Hospital, University of California, San Francisco (UCSF)
San Francisco, California, United States
Lisa Gail Winston, MD

Professor
UCSF
San Francisco, California, United States
JS

John Szumowski, MD

University of California, San Francisco
San Francisco, California, United States
Carina Marquez, MD, MPH

Associate Professor
Division of HIV, ID, Global Medicine, University of California San Francisco, Zuckerberg San Francisco General Hospital
San Francisco, CA, United States
NH

Nancy K. Hills, PhD

Professor
UCSF
Mill Valley, California, United States
Vivek Jain, MD, MAS (he/him/his)

Professor of Medicine
Division of HIV, Infectious Diseases & Global Medicine, San Francisco General Hospital, University of California, San Francisco
San Francisco, CA, United States